1. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
   Tomas Koltai et al, 2022, Cancers CrossRef
2. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
   Niklas Sturm et al, 2022, Cancers CrossRef
3. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment
   Ken Ohmine et al, 2015, Molecular Pharmaceutics CrossRef
4. Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
   Dae Wook Hwang et al, 2020, Annals of Hepato-Biliary-Pancreatic Surgery CrossRef
5. The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors
   Christine R. Cuthbertson et al, 2020, ACS Pharmacology & Translational Science CrossRef
6. Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine
   Justine M. Grixti et al, 2017, Frontiers in Pharmacology CrossRef
7. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
   Ahmad Hamad et al, 2021, World Journal of Gastroenterology CrossRef
8. Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies
   Jeffrey M Sutton, 2014, World Journal of Gastroenterology CrossRef